|
Description:
|
|
There are a range of different options for patients who require treatment escalation beyond dual or triple therapy, including premixed insulin, basal insulin plus mealtime insulin, and premixed GLP-1 RA and insulin. But how can we compare these different tactics, and going further, how do individual agents compare? Join Dr Tim Heise of the Profil Institute for an in-depth discussion of available trial data surrounding injectable therapies in type 2 diabetes.
References
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education. |